Revance Therapeutics reported $89.14M in Operating Expenses for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 9518M 611M
Adamas Pharmaceuticals ADMS:US 31.13M 2.29M
Aerie Pharmaceuticals AERI:US $ 58.69M 1.5M
ALKERMES ALKS:US 299.3M 29.33M
Antares Pharma ATRS:US $ 38.19M 1.5M
Biodelivery Sciences International BDSI:US $ 25.78M 7.8M
Bristol Myers Squibb BMY:US $ 9.99B 666M
Cara Therapeutics CARA:US $ 30.88M 5.38M
Coherus Biosciences CHRS:US $ 111.81M 138.59M
Eli Lilly And LLY:US $ 5336.7M 313.6M
Endo International Ordinary Shares ENDP:US $ 570.72M 35.49M
Flexion Therapeutics FLXN:US $ 45.06M 2.67M
Gw Pharmaceuticals GWPH:US 173.49M 2.46M
Horizon Pharma HZNP:US $ 694.03M 191.61M
JAZZ PHA JAZZ:US $ 821.4M 375.94M
Johnson & Johnson JNJ:US $ 16.65B 1.76B
Merk MRK:US $ 9905M 839M
Neurocrine Biosciences NBIX:US $ 226.1M 21M
Pacira Pharmaceuticals PCRX:US $ 100.75M 1.16M
Revance Therapeutics RVNC:US $ 89.14M 5.83M
Supernus Pharmaceuticals SUPN:US $ 107.22M 10.5M
Teva Pharmaceutical Industries TEVA:US 3.33B 220M
Zogenix ZGNX:US $ 74.22M 8.73M